NIH Identifies Priorities for Pediatric Therapeutics

In compliance with the Best Pharmaceuticals for Children Act (BPCA), NIH published a list of therapeutics identified by the agency as the highest priority for study in pediatric populations. The BPCA requires sponsors of drugs for adult indications to study pediatric indications if a disease occurs in children. NIH must update its priority list every three years.

• Hematologic Disease Priorities

• Pediatric Cancer Priorities